{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-041260","form_type":"8-K","ticker":"AZTR","cik":"0001701478","company_name":"Azitra, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.096827+00:00","generated_at":"2026-06-08T03:46:17.202220+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Azitra reports Q3 2023 net loss of $1.9M; cash $4.4M; pipeline advances for ATR-12 and ATR-04","bullets":["Net loss of $1.9M narrowed from $2.4M in Q3 2022; R&D expenses fell to $548,524 from $1.4M.","Cash and cash equivalents of $4.4M as of Sept 30, 2023; service revenue from related party of $310,700.","Lead program ATR-12 (Netherton syndrome) IND cleared; CRO hired; first patient enrollment expected in 2024.","ATR-04 (EGFRi-associated rash) advancing toward IND; upcoming milestones include preclinical data and IND submission.","Bayer joint development agreement progressing; royalty-bearing licensing agreement expected as next step."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-041260","json":"https://secwatch.observer/filing/0001493152-23-041260.json","markdown":"https://secwatch.observer/filing/0001493152-23-041260.md","text":"https://secwatch.observer/filing/0001493152-23-041260.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223041260/0001493152-23-041260-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223041260/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:46:17.202220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64936977efc9679ee03eb2a50a572da4158bca48","claim":"Azitra, Inc. reported the fiscal quarter ended September 30, 2023 results: net income $1.9 million.","evidence_excerpt":"On November 14, 2023, Azitra, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223041260/0001493152-23-041260-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended September 30, 2023"},{"label":"Net income","value":"$1.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}